Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Indoco Remedies Ltd
| Q2 FY26 Earnings Conference Call
Summary : Indoco Remedies reported Q2 FY26 revenue growth, driven by domestic and international formulations, with positive regulatory updates. Challenges include ongoing USFDA remediation costs and high debt.
Management Perspective positive : I'm happy to share that Q2 FY '26 is the first quarter when we begin to show an uptick in performance. I'm confident that with an increase in revenues going forward, with the continued control on costs and a focus on efficiency, which we all of which are currently being practiced in the company, we will soon go back to the days when we deliver a healthy and consistent financial performance going forward.
Concall Report Analysis & Insights
Business Overview
- Q2 FY26 standalone net revenues grew 8.8% YoY to INR4,293 million.
- Consolidated net revenues increased 9.6% YoY to INR4,718 million.
- Launched 6 new products in India, including anti-infectives and dental care.
- US FDA approved Rivaroxaban tablets and inspected API facility with zero observations.
- Domestic formulation business performed well, driven by anti-infectives and respiratory segments.
Future Growth Prospects
- Expect double-digit growth in Europe and UK business from Q3 FY26.
- API business shows strong growth, with a 40% increase quarter-on-quarter and year-on-year.
- Targeting INR3,500 crores revenue in three years, up from INR1,500 crores last year.
- Focus on vertically integrated products and expanding the OTC business in India.
- Anticipate FPP subsidiary to break even in a couple of quarters, WRPL OTC faster.
Management Insights
- Q2 FY26 marks the first quarter showing an uptick in performance after a difficult H2 last year.
- Confident in delivering healthy and consistent financial performance by controlling costs and focusing on efficiency.
- Strategic shift from pure contract manufacturing to front-ending in regulated markets.
- Reduced R&D spend by focusing on efficiency and vertically integrated products.
- Committed to repaying INR52 crores loan in H2 and INR140 crores next year.
Signs of Skepticism
- USFDA approval for Plant 2 lines is still pending despite readiness, causing delays.
- Other expenses increased quarter-on-quarter, contrary to expectations of reduction.
- Warren Remedies subsidiaries (FPP, WRPL) reported combined losses of INR23 crores.
- Europe revenue declined QoQ (INR63-64 crores in Q1 to INR55 crores in Q2).
- Breakeven for Warren Remedies OTC business is delayed from FY27 to potentially later.
Risk Factors
- Ongoing USFDA remediation costs at Plant 2 expected for two more quarters.
- Slow US FDA approval process for remaining sterile lines impacts revenue realization.
- Increased other expenses, including legal and travel, due to international business.
- Initial investment in OTC business will drain margins for 3-4 years.
- High debt profile and increased interest payments are a concern.
Good To Know
- Received Certificate of Merit Award from National Safety Council of Maharashtra Chamber for Patalganga plant.
- FPP subsidiary has licenses to operate in all US states and acts as a front-end for US business.
- WRPL includes OTC business with a manufacturing setup and API intermediates plant.
- Operating cash flow in Q2 was almost equal to that generated during the entire last year.
- Maintenance capex expected to be INR50-70 crores annually for the next 2-3 years.
Key Drivers
- USFDA approval for Plant 2 lines.
- Double-digit growth in Europe business.
- API business strong growth continues.
- OTC business expansion in India.
Key Analyst Discussions
Competitive Environment
- Company is ranked 31st in IPM for September '25 with 0.56% market share.
- Ranked 20th in IPM for prescription ranking as per September '25 data.
- Shifting from contract manufacturing to owning IP and commercializing products in regulated markets.
- OTC market has doubled in size, presenting a huge opportunity for brand creation.
- Focusing on metros for Indian business growth rather than increasing field force.
Market Trends & Consumer Behavior
- Anti-infective and respiratory segments performed well in Q2 due to seasonal factors.
- Cyclopam and Cital sales impacted by prolonged monsoon and lack of hot, moist summers.
- Indian business grew 11% in India, above IPM growth of 7-8%, despite seasonal portfolio.
- Market is hungry for sterile products despite Plant 2 issues.
- US market for generics is becoming unpredictable, leading to focus on volume builders.
Financial Highlights
- Management expects to hold consolidated other expenses at INR150-160 crores, despite current elevation.
- INR45 crores from fixed asset sales in H1 were from a sale and leaseback of Waluj plant equipment.
- Domestic formulation business has good margins, estimated higher than 20-25% EBITDA.
- Company aims to reduce R&D spend from 5% to 4% of sales by focusing on efficiency.
- Rising debt profile and increased interest payments are a concern for analysts.
Product Composition
- Launched 2 new antibiotics and expanded Cital portfolio to make it less seasonal.
- Introduced Drotitec (anti-spasmodic) and Macuchek (ophthalmology multivitamin).
- Launched Rinseoff mouthwash and gargle for respiratory ailments.
- Clarity Pharma agreement involves 15 new oral products, with 4-5 already launched in UK market.
- Sterile business is largely for US, with Europe serving as a backup strategy for US challenges.
Strategic Considerations
- Company is derisking US strategy by getting larger products approved via CMOs instead of further capex.
- US FDA acknowledged readiness for Plant 2 lines, expecting an audit soon.
- Europe business aims to reach INR300 crores run rate by next year.
- Warren Remedies OTC portfolio will remain restricted to Oral Care for now.
- Clarity Pharma collaboration is not exclusive, but Indoco intends to build products together.